CD33 and acute myeloid leukemia: We also performed a TCGA database analysis of LDLR mRNA expression in AML patients and compared this with CD33, SAMHD1, and PSA (prostate specific antigen), the latter serving as a negative control (Supplementary Fig. 5C).